The Wnt gene family has been implicated in normal mammary gland development, as well as in tumorigenesis in animal models and there is recent indirect evidence for perturbations of their signaling pathways in some cancer malignancies. However, investigation of Wnt genes and their role in human breast cancer have been severely hampered because their cell surface receptors have not yet been identified. A very recent major breakthrough strongly implicates membrane spanning molecules encoded by the multi gene frizzled family as their receptors. The applicant has developed novel approaches involving chimeric Wnt-IgG proteins to further study Wnt receptors. A major aim of this proposal is to establish the identity of the Wnt-2 receptor as a frizzled gene(s) using cells known to be susceptible to Wnt-2 transforming effects as the source. The applicant will then perform a systematic analysis of oncogenic activation of Wnt family members and their receptors in human breast tumors. Approaches will involve investigation of the role of autocrine transformation and alterations including gene amplification or other structural gene alterations that activate Wnt receptors. The applicant will also develop models in tissue culture to confirm that the genetic alterations observed contribute to neoplastic progression. Finally, the applicant will seek to gain insights into biochemical signaling properties of these receptors to aid in uncovering other aberrations in tumor cells. The molecular and immunologic reagents generated can then be assessed for their utility as molecular markers in diagnosis and/or prognosis of breast cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA071672-03
Application #
2895623
Study Section
Pathology B Study Section (PTHB)
Program Officer
Shen, Grace L
Project Start
1997-07-01
Project End
2000-06-30
Budget Start
1999-07-01
Budget End
2000-06-30
Support Year
3
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Mount Sinai School of Medicine
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
114400633
City
New York
State
NY
Country
United States
Zip Code
10029
Grumolato, Luca; Liu, Guizhong; Haremaki, Tomomi et al. (2013) ?-Catenin-independent activation of TCF1/LEF1 in human hematopoietic tumor cells through interaction with ATF2 transcription factors. PLoS Genet 9:e1003603
Shapiro, Mark; Akiri, Gal; Chin, Cynthia et al. (2013) Wnt pathway activation predicts increased risk of tumor recurrence in patients with stage I nonsmall cell lung cancer. Ann Surg 257:548-54
Vijayakumar, Sapna; Liu, Guizhong; Rus, Ioana A et al. (2011) High-frequency canonical Wnt activation in multiple sarcoma subtypes drives proliferation through a TCF/?-catenin target gene, CDC25A. Cancer Cell 19:601-12
Asciutti, S; Akiri, G; Grumolato, L et al. (2011) Diverse mechanisms of Wnt activation and effects of pathway inhibition on proliferation of human gastric carcinoma cells. Oncogene 30:956-66
Hall, Christopher L; Zhang, Honglai; Baile, Shobun et al. (2010) p21CIP-1/WAF-1 induction is required to inhibit prostate cancer growth elicited by deficient expression of the Wnt inhibitor Dickkopf-1. Cancer Res 70:9916-26
Grumolato, Luca; Liu, Guizhong; Mong, Phyllus et al. (2010) Canonical and noncanonical Wnts use a common mechanism to activate completely unrelated coreceptors. Genes Dev 24:2517-30
Akiri, G; Cherian, M M; Vijayakumar, S et al. (2009) Wnt pathway aberrations including autocrine Wnt activation occur at high frequency in human non-small-cell lung carcinoma. Oncogene 28:2163-72
Liu, Guizhong; Vijayakumar, Sapna; Grumolato, Luca et al. (2009) Canonical Wnts function as potent regulators of osteogenesis by human mesenchymal stem cells. J Cell Biol 185:67-75
Hall, Christopher L; Dubyk, Cara W; Riesenberger, Tracy A et al. (2008) Type I collagen receptor (alpha2beta1) signaling promotes prostate cancer invasion through RhoC GTPase. Neoplasia 10:797-803
Hall, Christopher L; Daignault, Stephanie D; Shah, Rajal B et al. (2008) Dickkopf-1 expression increases early in prostate cancer development and decreases during progression from primary tumor to metastasis. Prostate 68:1396-404

Showing the most recent 10 out of 25 publications